The first large-scale trial of an experimental Ebola vaccine has begun in Liberia.

About 30,000 people are expected to be injected with the drug starting from Monday, February 2.

The subjects, which include health workers and volunteers, will be administered with a small amount of the vaccine which carries safe genetic material of Ebola, tricking the human body into producing an immune response.

The trial is being conducted as part of a partnership between Liberia and the US.

Liberian Vice President, Joseph Nyumah Boakai told The Associated Press that the vaccines are "very important for Liberia and for the world."

The vaccine was developed by British pharmaceutical giant, GlaxoSmithKline in conjunction with the U.S. National Institutes of Health.